Search results for "costs"

showing 10 items of 332 documents

THE CHALLENGE OF OPEN TIBIAL SHAFT FRACTURES: WHEN TOMANAGE WITH EXTERNAL FIXATION AND WHEN TO USEINTRAMEDULLARY NAILING?

2020

Treatment of open tibial shaft fractures is challenging. External fixation (EF) is comparatively safe in treating these open injuries with the main advantages of easy application, minimal additional disruption, and convenient subsequent soft tissue repair. Tibial intramedullary nailing (IM) is optimal for the treatment of open tibial fractures. This study aims to report the outcomes of our multi-center experience in the management of open tibial shaft fractures, evaluating the efficacy and safety of using either the external fixation (EF) or intramedullary nailing (IM).In this study, clinical-radiographic results were evaluated in 26 cases of open fractures treated with an external fixator …

lcsh:R5-920open tibial diaphyseal fracturesexternal fixationhealth costsintramedullary nailoutcomeslcsh:Medicine (General)Euromediterranean Biomedical Journal
researchProduct

Evolutionary constraints of warning signals : a genetic trade-off between the efficacy of larval and adult warning coloration can maintain variation …

2016

To predict evolutionary responses of warning signals under selection, we need to determine the inheritance pattern of the signals, and how they are genetically correlated with other traits contributing to fitness. Furthermore, protective coloration often undergoes remarkable changes within an individual's lifecycle, requiring us to quantify the genetic constraints of adaptive coloration across all the relevant life stages. Based on a 12 generation pedigree with > 11,000 individuals of the wood tiger moth (Arctia plantaginis), we show that high primary defense as a larva (large warning signal) results in weaker defenses as adult (less efficient warning color), due to the negative genetic cor…

life-historywarning signalslife stageaposematismcosts of melanismgenetic correlations
researchProduct

Data from: Ecological conditions alter cooperative behaviour and its costs in a chemically defended sawfly

2018

The evolution of cooperation and social behaviour is often studied in isolation from the ecology of organisms. Yet, the selective environment under which individuals evolve is much more complex in nature, consisting of ecological and abiotic interactions in addition to social ones. Here we measured the life-history costs of cooperative chemical defence in a gregarious social herbivore, Diprion pini pine sawfly larvae, and how these costs vary under different ecological conditions. We ran a rearing experiment where we manipulated diet (resin content) and attack intensity by repeatedly harassing larvae to produce a chemical defence. We show that forcing individuals to allocate more to coopera…

medicine and health careautomimicrygenetic structuresDiprionidaefungiMedicineDiprion piniLife scienceslife-history costsantipredator defence
researchProduct

Data from: Ageing via perception costs of reproduction magnifies sexual selection

2018

Understanding what factors modulate sexual selection intensity is crucial to a wide variety of evolutionary processes. Recent studies show that perception of sex pheromones can severely impact male mortality when it is not followed by mating (perception costs of reproduction). Here, we examine the idea that this may magnify sexual selection by further decreasing the fitness of males with inherently low mating success, hence increasing the opportunity for sexual selection. We use mathematical modelling to show that even modest mortality perception costs can significantly increase variability in male reproductive success under a wide range of demographic conditions. We then conduct a series o…

medicine and health careperception costsLife SciencesMedicine
researchProduct

Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital se…

2007

As antifungal agents are frequently used in hematology and oncology, economic data on the empirical therapy of suspected systemic fungal infection are pivotal. Data were analyzed according to: (1) the rate of nephrotoxicity related to treatment with caspofungin in comparison to liposomal amphotericin B (L-AmB) from a randomized clinical trial, (2) the effect of nephrotoxicity on length of hospital stay from a European observational study, and (3) an example of total bottom-up cost in a department of hematology in Germany. All estimates include 95% confidence intervals (CI) using two-stage Monte Carlo simulation on binominal and Gaussian random variables from separate studies with comparable…

medicine.medical_specialtyAntifungal AgentsLiposomal amphotericin Blaw.inventionNephrotoxicitychemistry.chemical_compoundEchinocandinsLipopeptidesRandomized controlled trialDouble-Blind MethodlawCaspofunginBottom-up studyAmphotericin BInternal medicineAmphotericin BGermanymedicineHumansLongitudinal StudiesProspective StudiesProspective cohort studyIntensive care medicineNephrotoxicitybusiness.industryGeneral MedicineHematologybacterial infections and mycosesConfidence intervalEconomic evaluationchemistryMycosesLiposomesNumber needed to treatCosts and Cost AnalysisObservational studyOriginal ArticleCaspofunginbusinessmedicine.drugAnnals of Hematology
researchProduct

Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepati…

2004

Introduction: In adults with previously untreated chronic hepatitis C (CHC), the combination of peginterferon α-2a plus ribavirin produces a higher rate of sustained virological response (SVR) than interferon α-2b plus ribavirin, but it is still unproven whether this increase is cost effective. The objective of this study was to determine if the gain in SVR with peginterferon α-2a plus ribavirin is worth the incremental cost. Methods: We constructed a Markov model of disease progression in which cohorts of patients received peginterferon α-2a plus ribavirin or interferon α-2b plus ribavirin for 48 weeks (hepatitis C virus [HCV] genotype 1 and non-1 patients with fibrosis) or 24 weeks (genot…

medicine.medical_specialtyCirrhosisGenotypeCost effectivenessCost-Benefit AnalysisHepatitis C virusInterferon alpha-2medicine.disease_causeAntiviral AgentsSensitivity and SpecificityGastroenterologypeginterferon alpha2aPolyethylene Glycolschemistry.chemical_compoundchronic hepatitiInterferonInternal medicineRibavirinmedicineHumansRandomized Controlled Trials as Topicalpha2b interferonAntiviral AgentPharmacologybusiness.industryHealth PolicyRibavirinPublic Health Environmental and Occupational HealthInterferon-alphavirus diseasesHealth Care CostsHepatitis CHepatitis C Chronicmedicine.diseaseMarkov ChainsRecombinant Proteinsdigestive system diseasesModels EconomicTreatment OutcomechemistryImmunologyQuality of LifePeginterferon alfa-2bDrug Therapy CombinationbusinessPeginterferon alfa-2amedicine.drugPharmacoEconomics
researchProduct

Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Socie…

2020

This is a pre-copyedited, author-produced version of an article accepted for publication in European Journal of Preventive Cardiology following peer review. The version of record Piepoli, M.F., Abreu, A., Albus, C., Ambrosetti, M., Brotons, C., Catapano, A.L. ... Tiberi, M. (2020). Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology*. European Journal of Preventive Cardiology (EJPC), 27(2), 181-205 is available online at: https://doi.org/10.1177/2047487319893035. European guidelines on cardiovascular prevention in clinical practice were first published in 1994 and have been regu…

medicine.medical_specialtyConsensusEpidemiologyCost effectivenessCost-Benefit AnalysisPopulationCardiologyPsychological interventionphysical activitypopulationGuidelinesrisk managementsmokingrehabilitationlipidsprimary carepreventionhealthy lifestyleInternal medicinePreventive Health ServicesEpidemiologyHumansMedicineguidelineseducationpsychosocial factorsstakeholderRisk managementeducation.field_of_studyVDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin sosialmedisin: 801diabetesbusiness.industryStakeholderblood pressurerisk assessmentHealth Care CostsProtective FactorsPrognosisnutritionCardiovascular DiseasesHeart Disease Risk FactorsCardiologyPosition paperCardiology and Cardiovascular MedicinebusinessRisk assessmentclinical settings
researchProduct

Constipation severity is associated with productivity losses and healthcare utilization in patients with chronic constipation

2014

OBJECTIVE: We sought to evaluate the association between constipation severity, productivity losses and healthcare utilization in a national sample of Italian patients with chronic non-organic constipation (CC). METHODS: We enrolled 878 outpatients with CC. Clinical and demographic data were collected by physicians during clinical examinations. Patients completed a self-administered questionnaire (Patient Assessment of Constipation-Symptoms, PAC-SYM; Work Productivity and Activity Impairment; healthcare utilization, and Symptoms Checklist 90 Revised - Somatization Scale, SCL-90 R). RESULTS: Mean PAC-SYM score was 1.62 ± 0.69. Mean weekly sick time due to constipation was 2.7 ± 8.6 h and pro…

medicine.medical_specialtyConstipationChronic constipation; Cost-of-illness study; Direct cost; Functional constipation; Healthcare utilization; Indirect cost; Irritable bowel syndrome; Productivity loss; Oncology; Gastroenterologymacromolecular substancesIndirect costsdirect costMedicineIn patientIntensive care medicineProductivitycost-of-illness studyIrritable bowel syndromeirritable bowel syndromeChronic constipation; cost-of-illness study; direct cost; functional constipation; healthcare utilization; indirect cost; irritable bowel syndrome; productivity lossChronic constipationChronic constipationbusiness.industryGastroenterologyhealthcare utilizationfunctional constipationOriginal Articlesmedicine.diseaseproductivity lossOncologyHealthcare utilizationindirect costPhysical therapyFunctional constipationmedicine.symptombusinessUnited European Gastroenterology Journal
researchProduct

Cost-effectiveness and cost-utility analysis of the treatment of emotional disorders in primary care: psicap clinical trial. description of the sub-s…

2018

Introduction: In the primary care (PC) setting in Spain, the prevalence of emotional disorders (EDs) such as anxiety, depression and somatoform disorder is high. In PC patients, these disorders are not always managed in accordance with the recommendations provided by clinical practice guidelines, resulting in major direct and indirect economic costs and suboptimal treatment outcomes. The aim is to analyze and compare the cost-effectiveness and cost-utility of group-based psychological therapy versus treatment as usual (TAU). Methods: Multicenter, randomized controlled trial involving 300 patients recruited from PC centers in Madrid, Spain, with symptoms or possible diagnosis of anxiety, moo…

medicine.medical_specialtyCost effectivenesslcsh:BF1-990QALYslaw.inventionprimary care03 medical and health sciencesIndirect costs0302 clinical medicineRandomized controlled triallawmedicinePsychologyClinical Study Protocol030212 general & internal medicinecost-utilityGeneral PsychologyCost–utility analysisEmocionstransdiagnostic cognitive-behavioral therapy030227 psychiatryPatient Health QuestionnaireClinical triallcsh:PsychologyMoodemotional disordersPhysical therapyAnxietymedicine.symptomPsychology
researchProduct

Cost-effectiveness analysis of robot-assisted vs. open partial nephrectomy

2017

Background The cost-effectiveness of robot-assisted partial nephrectomy (RAPN) vs. the open procedure is not established. Methods We estimated in-hospital complications and the cost of RAPN vs. open partial nephrectomy (OPN) using an economic model. Costs incurred both intraoperatively and in hospital were considered. US data were extracted from existing literature. Results Mean in-hospital costs were $14,824 (95% CI $13,368-$16,898) for RAPN and $15,094 (95% CI $13,491-$17,140) for OPN. Complications after RAPN occurred in 23.3% (95% CI 20.0-25.8%) and after OPN in 36.1% (95% CI 35.6-36.6%) of the patients. In a sensitivity analysis, limited centre experience was associated with relevant i…

medicine.medical_specialtyCost-Benefit Analysismedicine.medical_treatment030232 urology & nephrologyBiophysicsNephrectomy03 medical and health sciencesPostoperative Complications0302 clinical medicineRobotic Surgical ProceduresmedicineHumansOpen partial nephrectomyHospital CostsComputer-assisted surgerybusiness.industryDecision TreesPerioperativeCost-effectiveness analysisNephrectomyComputer Science ApplicationsSurgeryModels EconomicTreatment Outcome030220 oncology & carcinogenesisSurgeryLower costbusinessThe International Journal of Medical Robotics and Computer Assisted Surgery
researchProduct